- Home
- RPAY vs BWAY Comparison
RPAY vs BWAY Comparison
Compare RPAY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | BWAY |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.0M | 337.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RPAY | BWAY |
|---|---|---|
| Price | $3.42 | $16.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $6.81 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 1.3M | 59.5K |
| Earning Date | 11-10-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $308,947,000.00 | $49,094,000.00 |
| Revenue This Year | $0.22 | $330.76 |
| Revenue Next Year | $6.91 | $22.24 |
| P/E Ratio | ★ N/A | $52.44 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $2.98 | $7.84 |
| 52 Week High | $8.37 | $18.18 |
Technical Indicators
Market Signals| Indicator | RPAY | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 55.03 |
| Support Level | $3.31 | $16.75 |
| Resistance Level | $3.52 | $18.18 |
| Average True Range (ATR) | 0.14 | 0.74 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 59.49 | 70.49 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.